Pharmaceuticals - Community Register

  

Community list of not active orphan medicinal products


WITHDRAWN  

Product information

Lumiliximab

EU orphan designation number: EU/3/08/528
Active ingredient: Lumiliximab
Indication: Treatment of chronic lymphocytic leukaemia
Sponsor: Biogen Idec Limited
Thames House, Foundation Park, Maidenhead, Berkshire, SL6 3UD, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
06/02/2008 Orphan Designation EMEA/OD/091/07 (2008)495 of 04/02/2008
22/04/2010 Removal of orphan designation from Community Register